Literature DB >> 23828322

Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review.

Sabrina Chiloiro1, Antonio Bianchi, Francesco Doglietto, Chiara de Waure, Antonella Giampietro, Alessandra Fusco, Donato Iacovazzo, Linda Tartaglione, Francesco Di Nardo, Francesco Signorelli, Libero Lauriola, Carmelo Anile, Guido Rindi, Giulio Maira, Alfredo Pontecorvi, Laura De Marinis.   

Abstract

Ki-67 Labeling Index is an immunocytochemical marker of cell proliferation. The correlation of Ki-67 expression with pituitary adenomas recurrence has been investigated and is highly debated. Aim of this study was to evaluate whether Ki-67 correlates with recurrence even in patients with an apparently completely removed pituitary adenoma. We retrospectively reviewed the database of the Hypothalamic-Pituitary Disease Unit at the Catholic University of Rome, collected between 2003 and 2011. Inclusion criteria were: patients who underwent surgery at the Department of Neurosurgery with an apparently complete removal of a pituitary adenoma; Ki-67 histological evaluation by the same operator and values of <3%. All patients underwent endocrine evaluation of the hypothalamic-pituitary function, ophthalmologic and neuro-radiological examinations, during the preoperative period and follow-up. Out of 490 patients recorded on the database of the Hypothalamic-Pituitary Disease Unit at the Catholic University of Rome, 191 cases met the inclusion criteria. Recurrence was observed in 49 cases (25.7% of the patients who had undergone radical excision). Optional cut-off value was identified at Ki-67 values of 1.50%. This was associated with worse disease-free survival time, even after correction for age at treatment, gender, positivity to p53, functional classification and Knosp grading. Ki-67 labeling index may be useful in postoperative management, even in patients who underwent radical PA removal. We suggest a Ki-67 cut-off value of 1.5% to plan an adequate clinical follow-up.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23828322     DOI: 10.1007/s11102-013-0500-6

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  39 in total

1.  Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.

Authors:  M Losa; A Franzin; F Mangili; M R Terreni; R Barzaghi; F Veglia; P Mortini; M Giovanelli
Journal:  Neurosurgery       Date:  2000-12       Impact factor: 4.654

2.  A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.

Authors:  Arvind Rishi; Mehar C Sharma; Chitra Sarkar; Deepali Jain; Manmohan Singh; Ashok Kumar Mahapatra; Veer Singh Mehta; Tapos Kumar Das
Journal:  Neurol India       Date:  2010 May-Jun       Impact factor: 2.117

3.  The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology.

Authors:  P C Burger; T Shibata; P Kleihues
Journal:  Am J Surg Pathol       Date:  1986-09       Impact factor: 6.394

4.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.

Authors:  E Delgrange; J Trouillas; D Maiter; J Donckier; J Tourniaire
Journal:  J Clin Endocrinol Metab       Date:  1997-07       Impact factor: 5.958

5.  Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.

Authors:  Mariagiovanna Filippella; Françoise Galland; Michèle Kujas; Jacques Young; Antongiulio Faggiano; Gaetano Lombardi; Annamaria Colao; Geri Meduri; Philippe Chanson
Journal:  Clin Endocrinol (Oxf)       Date:  2006-10       Impact factor: 3.478

6.  Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.

Authors:  Claudia Ramírez; Sonia Cheng; Guadalupe Vargas; Sylvia L Asa; Shereen Ezzat; Baldomero González; Lourdes Cabrera; Gerardo Guinto; Moisés Mercado
Journal:  J Clin Endocrinol Metab       Date:  2012-03-14       Impact factor: 5.958

7.  Predicting recurrence of nonfunctioning pituitary adenomas.

Authors:  Tae-Woong Noh; Hyeong Jae Jeong; Mi-Kyung Lee; Tai Seung Kim; Sun Ho Kim; Eun Jig Lee
Journal:  J Clin Endocrinol Metab       Date:  2009-10-09       Impact factor: 5.958

Review 8.  Ki-67 in pituitary neoplasms: a review--part I.

Authors:  Fateme Salehi; Anne Agur; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd; Michael Cusimano
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

Review 9.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

10.  Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.

Authors:  H E Turner; Z Nagy; K C Gatter; M M Esiri; J A Wass; A L Harris
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  22 in total

Review 1.  Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis.

Authors:  Yihuan Luo; Fanghui Ren; Yongru Liu; Zhenhong Shi; Zhong Tan; Huojie Xiong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Relation of apparent diffusion coefficient with Ki-67 proliferation index in meningiomas.

Authors:  Ozdil Baskan; Gokalp Silav; Fatih Han Bolukbasi; Ozlem Canoz; Serdar Geyik; Ilhan Elmaci
Journal:  Br J Radiol       Date:  2015-11-05       Impact factor: 3.039

3.  Differential DNA methylome profiling of nonfunctioning pituitary adenomas suggesting tumour invasion is correlated with cell adhesion.

Authors:  Ye Gu; Xinyao Zhou; Fan Hu; Yong Yu; Tao Xie; Yuying Huang; Xinzhi Zhao; Xiaobiao Zhang
Journal:  J Neurooncol       Date:  2016-05-11       Impact factor: 4.130

Review 4.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

5.  Relationship of intraoperative ultrasound characteristics with pathological grades and Ki-67 proliferation index in intracranial gliomas.

Authors:  Ozdil Baskan; Gokalp Silav; Ramazan Sari; Ozlem Canoz; Ilhan Elmaci
Journal:  J Med Ultrason (2001)       Date:  2014-11-22       Impact factor: 1.314

6.  Microsurgical therapy of pituitary adenomas.

Authors:  Pietro Mortini; Lina Raffaella Barzaghi; Luigi Albano; Pietro Panni; Marco Losa
Journal:  Endocrine       Date:  2017-10-24       Impact factor: 3.633

7.  Synchronous bilateral adrenalectomy in ACTH-dependent hypercortisolism: predictors, biomarkers and outcomes.

Authors:  A Pontecorvi; A Bianchi; S Chiloiro; A Giampietro; M Raffaelli; G D'Amato; C Bima; L Lauretti; C Anile; C P Lombardi; G Rindi; R Bellantone; L De Marinis
Journal:  Endocrine       Date:  2019-10-03       Impact factor: 3.633

Review 8.  Aggressive pituitary adenomas--diagnosis and emerging treatments.

Authors:  Antonio Di Ieva; Fabio Rotondo; Luis V Syro; Michael D Cusimano; Kalman Kovacs
Journal:  Nat Rev Endocrinol       Date:  2014-05-13       Impact factor: 43.330

9.  Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.

Authors:  Marialaura Del Basso De Caro; Domenico Solari; Francesca Pagliuca; Alessandro Villa; Elia Guadagno; Luigi Maria Cavallo; Annamaria Colao; Guido Pettinato; Paolo Cappabianca
Journal:  Neurosurg Rev       Date:  2016-05-23       Impact factor: 3.042

10.  Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

Authors:  Wen Lyu; Xu Fei; Cheng Chen; Yuqun Tang
Journal:  Gland Surg       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.